Vilacto Bio (VIBI) 10-Q 20 Aug 18 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jun. 30, 2018	Jul. 31, 2018
Document And Entity Information
Entity Registrant Name	Vilacto Bio Inc.
Entity Central Index Key	1,576,724
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		90,000,000
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,019

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Current assets
Cash	$ 48,739	$ 148,767
Accounts receivable	44	36
Inventory	100,217	100,413
Prepaid expenses	43,452	59,658
Total current assets	192,452	308,874
Intangible assets, net	5,697	896
Total assets	198,149	309,770
Current liabilities
Accounts payable and accrued liabilities	30,659	35,780
Due to related parties	263,672	240,952
Convertible loans	119,688	32,607
Derivative liabilties	460,923	729,737
Loans	174,000	174,000
Loans from related parties	32,608	32,608
Total current liabilities	1,081,550	1,245,684
Total liabilities	1,081,550	1,245,684
Common stock; $0.001 par value; 1,125,000,000 shares authorized; 90,000,000 and 90,000,000 shares issued and outstanding as of June 30, 2018 and March 31, 2018, respectively	90,000	90,000
Additional paid-in capital	(22,000)	(22,000)
Accumulated earnings (deficit)	(951,401)	(1,003,914)
Total stockholders' equity (deficit)	(883,401)	(935,914)
Total liabilities and stockholders' equity (deficit)	$ 198,149	$ 309,770

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Mar. 31, 2018
Stockholders' equity
Common stock, par value	$ 0.001
Common stock shares, authorized	1,125,000,000
Common stock shares, issued	90,000,000
Common stock shares, outstanding	90,000,000	90,000,000

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenues	$ 430
Cost of revenues	230
Gross profit	200
Operating expenses
Royalty expense	30,000	30,000
Professional fees	20,895	22,785
General and administrative expenses	66,586	19,015
Depreciation and amortization expense	199
Total operating expenses	117,680	71,800
Loss from operations	(117,480)	(71,800)
Other income (expense)
Gain (loss) on derivative liabilities	268,814
Interest expense	(98,821)	(1,230)
Total other income (expense)	169,993	1,230
Net income (loss)	$ 52,513	$ (73,030)
Basic income (loss) per common share	$ 0	$ 0
Basic weighted average common shares outstanding	90,000,000	90,000,000

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash Flows from Operating Activities
Net income (loss)	$ 52,513	$ (73,030)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	199
(Gain) Loss on derivative liability	(268,814)
Amortization of debt discount	78,048
Amortization of original issue discount	1,870
Amortization of debt issuance costs	7,163
Changes in assets and liabilities
(Increase) decrease in accounts receivable	(8)
(Increase) decrease in prepaid expense	16,206	(139)
(Increase) decrease in inventory	196
Increase (decrease) in accounts payable	10,692	(3,844)
Net cash from operating activities	(101,935)	(77,013)
Cash Flows from investing
Purchase of intangible assets	5,000
Net cash used in investing activities	(5,000)
Cash Flows from Financing Activities
Proceeds from promissory notes		22,500
Proceeds from convertible promissory notes
Advance from related parties	6,907	35,604
Payments on advance from related parties
Net cash from financing activities	6,907	58,104
Net increase (decrease) in Cash	(100,028)	(18,909)
Beginning cash balance	148,767	22,020
Ending cash balance	48,739	3,111
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for tax

Organization and Line Business

Organization and Line Business	3 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
ORGANIZATION AND LINE BUSINESS	1. ORGANIZATION AND LINE BUSINESS The Company was originally incorporated under the laws of the state of Nevada on February 25, 2013. The Company is devoting substantially all of its present efforts to establish a new business and has had minimal revenues from operations to date. On April 4, 2017, the Company entered into a license agreement (the “License Agreement”) with Pharma GP APS, a Company controlled by our CEO. (“Pharma GP”) and acquired an exclusive license to sell certain cosmetic products or ingredients covered by United States Patent No. US 8,637,075 in the territory of the United States. As a result of the License Agreement, the Company is currently marketing a line of skin care products on its website at www.vilacto.com. These products include, lotions, skin care creams and gels, lip balms, foot creams and oils, and similar items. On April 19, 2017, the Company also entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Pharma GP and its sole shareholder, 9 Heroes APS, a Denmark corporation controlled by our CEO (together, “Seller”). In accordance with the terms of the Purchase Agreement, the Company agreed to purchase all of the outstanding shares of Pharma GP for the purchase price (the “Purchase Price”) of $6,000,000, payable as $3,000,000 in cash and the balance in shares of our common stock. The closing of the above transactions will likely not occur until the Company is able to successfully raise capital for the Purchase Price.

Basis of Presentation and Going

Basis of Presentation and Going Concern	3 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
BASIS OF PRESENTATION AND GOING CONCERN	2. BASIS OF PRESENTATION AND GOING CONCERN The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted. Going concern

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. SUMMARY OF SIGNIFICANT POLICIES This summary of significant accounting policies of Vilacto Bio Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements. Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Revenue Recognition Accounts Receivable Cash and cash equivalents Concentration Risk At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of June 30, 2018, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts. Fair Value of Financial Instruments As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Stock-based compensation Compensation-Stock Compensation, Non-Employee Stock Based Compensation Earnings (loss) per share Earnings Per Share, Long-lived Assets Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms in agreements are reviewed to determine whether or not they contain embedded derivatives that are required under ASC 815 to be accounted for and separated from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities is required to be revalued at each reporting date, with the corresponding changes in fair value recorded in current period operating results. Inventory Income taxes Income Taxes Segment Reporting Recently Issued Accounting Pronouncements Revenue from Contracts with Customers In July 2015, the FASB made a decision to defer the effective date of the new standard for one year and permit early adoption as of the original effective date. The Company has reviewed its revenue streams and does not believe that the adoption of this standard has a material effect on its revenue recognition in 2017 or 2018.

Inventory

Inventory	3 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
INVENTORY	4. INVENTORY Inventory consist of the following as of June 30, 2018 and March 31, 2018: June 30, 2018 March 31, 2018 Raw materials $ — $ — Finished Goods 100,217 100,413 Total $ 100,217 $ 100,413

Prepaid Expenses

Prepaid Expenses	3 Months Ended
	Jun. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES	5. PREPAID EXPENSES Prepaid expenses consist of the following as of June 30, 2018 and March 31, 2018: June 30, 2018 March 31, 2018 Prepaid Marketing $ 43,452 $ 59,568 Total prepaid expenses $ 43,452 $ 59,568

Intangible Assets

Intangible Assets	3 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	6. INTANGIBLE ASSETS Patents and trademarks and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. Intangible assets consist of the following as of June 30, 2018 and March 31, 2018: June 30, 2018 March 31, 2018 Patents and trademarks $ 920 $ 920 Website 5,000 — Less: accumulated depreciation (223) (24) Fixed assets, net of accumulated depreciation $ 5,697 $ 896 Amortization expense for the three months ended June 30, 2018 and 2017 was $199 and $0, respectively.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	7. CONVERTIBLE NOTES PAYABLE Convertible Notes Payable at consists of the following: June 30, 2018 Auctus Fund, LLC On February 26, 2018, we entered into a Securities Purchase Agreement (the “Auctus SPA”), under which we agreed to sell a 12% convertible promissory note in an aggregate principal amount of $167,750 (the “Auctus Note”) to Auctus Fund, LLC (“Auctus”). The Auctus Note will bear interest at a rate of 12% per annum and will mature on November 26, 2018. The net proceeds of the sale of the Auctus Note, after deducting the expenses payable by were $150,000. At any time after the issue date of the Auctus Note, Auctus has the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Auctus Note into shares of our common stock at the Conversion Price. The “Conversion Price” will be the lesser of (i) the lowest trading price of our common stock during the twenty-five-day trading period prior to the issue date of the Auctus Note and (ii) 50% of the lowest trading price of our common stock during the twenty-five-day trading period prior to the conversion. The Conversion Price is subject to further reduction upon certain events specified in the Auctus Note. We have the right to prepay the Auctus Note at any time until the 180th calendar day after the issue date of the Auctus Note, in an amount equal to 150% (or 135% if we prepay the Auctus Note on or before the date that is 90 days after the issue date of the Auctus Note) of the outstanding balance of the Auctus Note (including principal and accrued and unpaid interest). We may not prepay the Auctus Note after the 180th calendar day after the issue date of the Auctus Note. We will be subject to a liquidated damages charge of 25% of the outstanding principal amount of the Auctus Note if we effect certain exchange transactions in accordance with, based upon or related or pursuant to Section 3(a)(10) of the Securities Act. In addition, the Auctus Note grants Auctus the right to update the terms of the Auctus SPA and the Auctus Note to incorporate the terms of any future transaction document related to a security issuance by us to a third party that are more favorable to the third party than the terms of the Auctus SPA and the Auctus Note. Any amounts due and payable to Auctus under the terms of the Auctus Note, including any payment on an event of default, default interest, or agreed upon liquidated damages may, at the Auctus's option, be converted into shares of our common stock at the Conversion Price. Pursuant to a Registration Rights Agreement, we are required to register 30,000,000 shares into which the Auctus Note may be converted. During the three months ending June 30, 2018 the Company recorded interest of $5,019 The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $55,917 during the three months ended June 30, 2018. $ 167,750 Unamortized debt discount (91,556) Total, net of unamortized discount 76,194 EMA Financial, LLC On February 23, 2018 we entered into a Securities Purchase Agreement (“EMA SPA”) with EMA Financial, LLC, a Delaware limited liability company (“EMA”), pursuant to which we issued and sold to EMA a convertible promissory note, dated February 23, 2018 in the principal amount of $125,000 (the “EMA Note”). In connection with the foregoing, we also entered into a Registration Rights Agreement with the Purchaser dated February 23, 2018 (the “Registration Rights Agreement”). The EMA Note as amended, is due February 23, 2019, bears interest at the rate of 12% per annum. All principal and accrued interest on the EMA Note is convertible into shares of our common stock at the election of EMA at any time at a conversion price equal to the lesser of (i) the trading price for our common stock on the trading day prior to the closing date of the EMA Note, or (ii) a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the EMA Note within 90 days of the closing date at a premium of 135% of all amounts owed to EMA and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the EMA Note more than 180 days after the closing date. The EMA Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. Pursuant to the Registration Rights Agreement, we are required to register 30,000,000 shares into which the EMA Note may be converted. During the three months ending June 30, 2018 the Company recorded interest of $3,740 The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $31,164 during the three months ended June 30, 2018. 125,000 Unamortized debt discount (81,506) Total, net of unamortized discount 43,494 Total $ 119,688 Derivative liability The Company accounts for the fair value of the conversion features of its convertible debt in accordance with ASC Topic No. 815-15 “Derivatives and Hedging; Embedded Derivatives” (“Topic No. 815-15”). Topic No. 815-15 requires the Company to bifurcate and separately account for the conversion features as an embedded derivative contained in the Company’s convertible debt. The Company is required to carry the embedded derivative on its balance sheet at fair value and account for any unrealized change in fair value as a component of results of operations. The Company values the embedded derivatives using the Black-Scholes pricing model. The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of June 30, 2018: Amount Balance March 31, 2017 — Debt discount originated from derivative liabilities 262,500 Initial loss recorded 170,924 Adjustment to derivative liability due to debt settlement — Change in fair market value of derivative liabilities 296,313 Balance March 31, 2018 $ 729,737 Debt discount originated from derivative liabilities — Initial loss recorded — Adjustment to derivative liability due to debt settlement — Change in fair market value of derivative liabilities (268,814) Balance June 30, 2018 $ 460,923 The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible notes and at March 31, 2018 and June 30, 2018: Fair value assumptions – derivative notes: February 23, 2018 February 26, 2018 March 31, 2018 June 30, 2018 Risk free interest rate 2.02 % 2.03 % 2.09 % 2.33% Expected term (years) 1.0 .75 0.66 -.90 0.41-0.65 Expected volatility 188.62 % 188.72 % 199.58 % 170.79% Expected dividends 0 0 0 0

Loans Payable

Loans Payable	3 Months Ended
	Jun. 30, 2018
Receivables [Abstract]
LOANS PAYABLE	8. LOANS PAYABLE On January 8, 2018, the Company and four lenders assigned the rights and obligations of a total of $174,500 in promissory notes to a new lender, the terms of the note were unchanged. The notes bear interest at a rate of 5% per annum and is due within two business days of demand notice. During the three months ending June 30, 2018 the Company recorded interest of $2,169.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
STOCKHOLDERS' EQUITY	9. STOCKHOLDERS’ EQUITY On March 6, 2017, our board of directors resolved to increase the number of authorized shares of our common stock, par value $0.001, from 75,000,000 shares to 1,125,000,000 shares. Correspondingly, our board of directors affirmed a forward split of 15 for 1 in which each shareholder will be issued 15 common shares in exchange for 1 common share of their currently issued common stock. In accordance with ASC 505-20 all stock-related information presented in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the number of shares resulting from this action. Prior to approval of the forward split, we had a total of 6,000,000 issued and outstanding common shares, par value $0.001. On the effective date of the forward split, we had a total of 90,000,000 issued and outstanding common shares, par value $0.001. Overview The Company is authorized to issue 1,125,000,000 shares of $0.001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company. As of June 30, 2018, there were 90,000,000 shares of common stock issued and outstanding. Stock purchase agreement On April 19, 2017, we entered into a Stock Purchase Agreement (the “Agreement”) with Pharma GP APS, a Denmark corporation controlled by our CEO (“Pharma GP”) and its sole shareholder, 9 Heroes APS, a Denmark corporation controlled by our CEO. In accordance with the terms of the Agreement, we agreed to purchase all of the outstanding shares of Pharma GP for the purchase price (the “Purchase Price”) of $6,000,000, payable as $3,000,000 in cash and the balance in shares of our common stock. The closing of the above transactions is expected to occur when the company has sufficient funds to do so. The Agreement is conditioned on our paying the Purchase Price, obtaining financing in the amount of $4,000,000 for operational expenses, and receiving audited financial statements from Pharma GP, among other conditions as contained in the Agreement. We currently do not have the money on hand to pay the Purchase Price, and we must obtain additional financing to meet the conditions to close the transaction. The Agreement includes customary representations, warranties and covenants among the parties to each other as of specific dates. The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, which is included as an exhibit our Current Report on Form 8-K filed on April 20, 2017 and is incorporated by reference herein. Pharma GP is a manufacturer of skincare products with distribution in several countries. The company’s body and facial creams are designed for moisturizing, skin regeneration, wound healing and a variety of skin issues, such as dry and cracked skin, among other things. In addition, Pharma GP owns patents, trademarks and production facilities for an ingredient designed to be used in pharmaceuticals and medical devices for treating a wide range of issues. Pharma GP currently has skincare products that are available over the counter. However, the company intends to develop, market and sell pharmaceutical skincare products to treat various ailments using its patented technology. Currently, the company has no government approved products, but with the financing, we intend to purchase Pharma GP and focus on those clinical applications. We expect to have more information on the status of the Closing of the Agreement and our new business direction in future filings.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
RELATED PARTY TRANSACTIONS	10. RELATED PARTY TRANSACTIONS In connection with an assumption of the debt agreement the Company executed a $32,608 promissory note with Mr. Anderson which bears interest at a rate of 10% per annum. During the three months ending June 30, 2018 the Company recorded interest of $813. During the three months ending June 30, 2018, Gert Anderson, the President and CEO of the Company advanced $6,907 to the Company to pay expenses on behalf of the Company. As of June 30, 2018, $59,293 in advances remain outstanding. The advances bear no interest, are unsecured, and are due on demand.

Royalty Agreement

Royalty Agreement	3 Months Ended
	Jun. 30, 2018
Research and Development [Abstract]
ROYALTY AGREEMENT	11. ROYALTY AGREEMENT License agreement On April 4, 2017, we entered into a license agreement (the “License Agreement”) with Pharma GP APS, a Company controlled by our CEO. (“Pharma GP”) and acquired an exclusive license to sell certain cosmetic products or ingredients covered by United States Patent No. US 8,637,075 in the territory of the United States. For the license, we agreed to pay to GP a royalty of eight percent (8%) on the selling price (irrespective of any taxes, custom duties, costs of insurance, transportation costs or other costs) for all licensed product we sell in the United States (if in excess of the agreed minimum royalty), or pay the agreed minimum royalty of $10,000 per month. During the three months ending June 30, 2018 , the Company recorded royalty expense of $30,000 related to this agreement. Under the License Agreement, we have the ability to sublicense to third parties under the royalty arrangement described above.

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENT The Company has evaluated events subsequent to the balance sheet through the issuance date of these financial statements in accordance with FASB ASC 855 and has determined that there are no such events that would require adjustment to, or disclosure in, the financial statements except as disclosed below. Adar Bays, LLC July 2, 2018 Convertible Note On July 2, 2018 we entered into a Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 2, 2018 in the principal amount of $150,000 (the “July 2, 2018 Adar Note”). The July 2, 2018 Adar Note, is due July 2, 2019, bears interest at the rate of 10% per annum. All principal and accrued interest on the July 2, 2018 Adar Note is convertible into shares of our common stock at the election of Adar six months after the issuance date at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We can pay the note in cash within the first six months of issuance, we have no right to prepay the July 2, 2018 Adar Note six months and one day after issuance. The July 2, 2018 Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. GS Capital Partners, LLC Convertible Note On July 11, 2018 we entered into a Convertible note with GS Capital Bays, LLC (“GS”) pursuant to which we issued a convertible promissory note, dated July 11, 2018 in the principal amount of $110,000 (the “GS Note”). The GS Note, is due July 11, 2019, bears interest at the rate of 10% per annum. All principal and accrued interest on the GS Note is convertible into shares of our common stock at the election of GS at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the GS Note within 60 days of the closing date at a premium of 125% of all amounts owed to GS and at a premium of 135% if prepaid more than 60 but less than 120 days following the closing date, at a premium of 145% if prepaid more than 120 but less than 180 days following the closing date. We have no right to prepay the GS Note more than 180 days after the closing date. The GS Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. Eagle Equities, LLC Convertible Note On July 20, 2018 we entered into a Convertible note with Eagle Equities, LLC (“Eagle”) pursuant to which we issued a convertible promissory note, dated July 20, 2018 in the principal amount of $100,000 (the “Eagle Note”). The Eagle Note, is due July 20, 2019, bears interest at the rate of 10% per annum. All principal and accrued interest on the Eagle Note is convertible into shares of our common stock at the election of Eagle at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Eagle Note within 90 days of the closing date at a premium of 135% of all amounts owed to GS and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Eagle Note more than 180 days after the closing date. The Eagle Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. Adar Bays, LLC July 23, 2018 Convertible Note On July 23, 2018 we entered into a Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 23, 2018 in the principal amount of $50,000 (the “Adar Note”). The Adar Note, is due July 23, 2019, bears interest at the rate of 10% per annum. All principal and accrued interest on the Adar Note is convertible into shares of our common stock at the election of Adar at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Adar Note within 90 days of the closing date at a premium of 135% of all amounts owed to Adar and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Adar Note more than 180 days after the closing date. The Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties.

Summary Of Significant Accoun18

Summary Of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2018
Summary Of Significant Accounting Policies Policies
Accounts Receivable	Accounts Receivable
Cash and Cash Equivalents	Cash and cash equivalents
Earnings per Share	Earnings (loss) per share Earnings Per Share,
Fair Value of Financial Instruments	Fair Value of Financial Instruments As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
Income Taxes	Income taxes Income Taxes
Revenue Recognition	Revenue Recognition
Use of Estimates	Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Recent Accounting Pronouncements	Recently Issued Accounting Pronouncements Revenue from Contracts with Customers In July 2015, the FASB made a decision to defer the effective date of the new standard for one year and permit early adoption as of the original effective date. The Company has reviewed its revenue streams and does not believe that the adoption of this standard has a material effect on its revenue recognition in 2017 or 2018.
Concentration Risk	Concentration Risk At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of June 30, 2018, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.
Stock Based Compensation	Stock-based compensation Compensation-Stock Compensation,
Non-Employee Stock Based Compensation	Non-Employee Stock Based Compensation
Long Lived Assets	Long-lived Assets
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms in agreements are reviewed to determine whether or not they contain embedded derivatives that are required under ASC 815 to be accounted for and separated from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities is required to be revalued at each reporting date, with the corresponding changes in fair value recorded in current period operating results.
Segment Reporting	Segment Reporting
Inventory	Inventory

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventory	June 30, 2018 March 31, 2018 Raw materials $ — $ — Finished Goods 100,217 100,413 Total $ 100,217 $ 100,413

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	3 Months Ended
	Jun. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	June 30, 2018 March 31, 2018 Prepaid Marketing $ 43,452 $ 59,568 Total prepaid expenses $ 43,452 $ 59,568

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	June 30, 2018 March 31, 2018 Patents and trademarks $ 920 $ 920 Website 5,000 — Less: accumulated depreciation (223) (24) Fixed assets, net of accumulated depreciation $ 5,697 $ 896

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Convertible Notes Payable	Convertible Notes Payable at consists of the following: June 30, 2018 Auctus Fund, LLC On February 26, 2018, we entered into a Securities Purchase Agreement (the “Auctus SPA”), under which we agreed to sell a 12% convertible promissory note in an aggregate principal amount of $167,750 (the “Auctus Note”) to Auctus Fund, LLC (“Auctus”). The Auctus Note will bear interest at a rate of 12% per annum and will mature on November 26, 2018. The net proceeds of the sale of the Auctus Note, after deducting the expenses payable by were $150,000. At any time after the issue date of the Auctus Note, Auctus has the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Auctus Note into shares of our common stock at the Conversion Price. The “Conversion Price” will be the lesser of (i) the lowest trading price of our common stock during the twenty-five-day trading period prior to the issue date of the Auctus Note and (ii) 50% of the lowest trading price of our common stock during the twenty-five-day trading period prior to the conversion. The Conversion Price is subject to further reduction upon certain events specified in the Auctus Note. We have the right to prepay the Auctus Note at any time until the 180th calendar day after the issue date of the Auctus Note, in an amount equal to 150% (or 135% if we prepay the Auctus Note on or before the date that is 90 days after the issue date of the Auctus Note) of the outstanding balance of the Auctus Note (including principal and accrued and unpaid interest). We may not prepay the Auctus Note after the 180th calendar day after the issue date of the Auctus Note. We will be subject to a liquidated damages charge of 25% of the outstanding principal amount of the Auctus Note if we effect certain exchange transactions in accordance with, based upon or related or pursuant to Section 3(a)(10) of the Securities Act. In addition, the Auctus Note grants Auctus the right to update the terms of the Auctus SPA and the Auctus Note to incorporate the terms of any future transaction document related to a security issuance by us to a third party that are more favorable to the third party than the terms of the Auctus SPA and the Auctus Note. Any amounts due and payable to Auctus under the terms of the Auctus Note, including any payment on an event of default, default interest, or agreed upon liquidated damages may, at the Auctus's option, be converted into shares of our common stock at the Conversion Price. Pursuant to a Registration Rights Agreement, we are required to register 30,000,000 shares into which the Auctus Note may be converted. During the three months ending June 30, 2018 the Company recorded interest of $5,019 The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $55,917 during the three months ended June 30, 2018. $ 167,750 Unamortized debt discount (91,556) Total, net of unamortized discount 76,194 EMA Financial, LLC On February 23, 2018 we entered into a Securities Purchase Agreement (“EMA SPA”) with EMA Financial, LLC, a Delaware limited liability company (“EMA”), pursuant to which we issued and sold to EMA a convertible promissory note, dated February 23, 2018 in the principal amount of $125,000 (the “EMA Note”). In connection with the foregoing, we also entered into a Registration Rights Agreement with the Purchaser dated February 23, 2018 (the “Registration Rights Agreement”). The EMA Note as amended, is due February 23, 2019, bears interest at the rate of 12% per annum. All principal and accrued interest on the EMA Note is convertible into shares of our common stock at the election of EMA at any time at a conversion price equal to the lesser of (i) the trading price for our common stock on the trading day prior to the closing date of the EMA Note, or (ii) a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the EMA Note within 90 days of the closing date at a premium of 135% of all amounts owed to EMA and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the EMA Note more than 180 days after the closing date. The EMA Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. Pursuant to the Registration Rights Agreement, we are required to register 30,000,000 shares into which the EMA Note may be converted. During the three months ending June 30, 2018 the Company recorded interest of $3,740 The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $31,164 during the three months ended June 30, 2018. 125,000 Unamortized debt discount (81,506) Total, net of unamortized discount 43,494 Total $ 119,688
Derivative liabilities associated with Convertible Debt	Amount Balance March 31, 2017 — Debt discount originated from derivative liabilities 262,500 Initial loss recorded 170,924 Adjustment to derivative liability due to debt settlement — Change in fair market value of derivative liabilities 296,313 Balance March 31, 2018 $ 729,737 Debt discount originated from derivative liabilities — Initial loss recorded — Adjustment to derivative liability due to debt settlement — Change in fair market value of derivative liabilities (268,814) Balance June 30, 2018 $ 460,923
Black-Scholes Model	Fair value assumptions – derivative notes: February 23, 2018 February 26, 2018 March 31, 2018 June 30, 2018 Risk free interest rate 2.02 % 2.03 % 2.09 % 2.33% Expected term (years) 1.0 .75 0.66 -.90 0.41-0.65 Expected volatility 188.62 % 188.72 % 199.58 % 170.79% Expected dividends 0 0 0 0

Organization and Line Business

Organization and Line Business (Details Narrative)	3 Months Ended
	Jun. 30, 2018USD ($)
Notes to Financial Statements
State Country Name	State of Nevada
Date of incorporation	Feb. 25, 2013
Date of license agreement with Pharma GP ApS	Apr. 4, 2017
Date of Stock Purchase Agreement	Apr. 19, 2017
Purchase price of Pharma GP outstanding shares	$ 6,000,000
Payable in cash	$ 3,000,000

Basis of Presentation and Goi24

Basis of Presentation and Going Concern (Details Narrative) - USD ($)	3 Months Ended		52 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018
Going Concern Details Narrative
Net loss	$ 52,513	$ (73,030)	$ 951,401

Summary of Significant Policies

Summary of Significant Policies (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018
Accounting Policies [Abstract]
Revenues	430	0
Allowance for doubfult accounts	$ 44		$ 36
Cash and Cash Equivalents	48,739		$ 148,767
Cash in excess of FDIC limits	$ 0

Inventory (Details)

Inventory (Details) - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Inventory Disclosure [Abstract]
Raw Materials
Finished Goods	100,217	100,413
Total	$ 100,217	$ 100,413

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Marketing	$ 43,452	$ 59,568
Prepaid fees
Total prepaid expenses	$ 43,452	$ 59,568

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and Trademarks	$ 920	$ 920
Webiste	5,000
Less: accumulated depreciation	(223)	(24)
Fixed assets, net of accumulated depreciation	$ 5,697	$ 896

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Amortization Expense	$ 199	$ 0

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Conversions of Stock (Details)	Jun. 30, 2018USD ($)
Convertible Notes Payable	$ 119,688
Convertible Note 1
Convertible Note Payable	167,750
Unamortized debt discount	(91,556)
Total Net of Unamortized Discount	76,194
Convertible Note 2
Convertible Note Payable	125,000
Unamortized debt discount	(81,506)
Total Net of Unamortized Discount	$ 43,494

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	3 Months Ended
	Jun. 30, 2018USD ($)shares
Convertible Note 1
Mayurity Date	Nov. 26, 2018
Net Proceeds	$ 150,000
Financing expense	$ 55,917
Required Shares to Register | shares	30,000,000
Convertible Note 2
Mayurity Date	Feb. 23, 2019
Financing expense	$ 31,164
Required Shares to Register | shares	30,000,000
Convertible Note One
Convertible Notes Payable, Value	$ 167,750
Interest Rate	12.00%
Accrued Interest	$ 5,019
Convertible Note Two
Convertible Notes Payable, Value	$ 125,000
Interest Rate	12.00%
Accrued Interest	$ 3,740

Convertible Notes Payable - Der

Convertible Notes Payable - Derivative Liabilities (Details) - USD ($)	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt Discount originated from Derivative Liabilities		$ 262,500
Initial Loss Recorded		170,924
Adjustment to Derivative Liability due to debt settlement
Change in fair market value	(268,814)	296,313
Balance	$ 460,923	$ 729,737

Convertible Notes Payable - Fai

Convertible Notes Payable - Fair Value Assumptions (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Feb. 26, 2018	Feb. 23, 2018	Jun. 30, 2018	Mar. 31, 2018
Debt Disclosure [Abstract]
Risk free interest rate	203.00%	202.00%	233.00%	209.00%
Expected term in years	9 months	1 year	5 months 2 days	7 months 16 days
Expected term in years maximum			7 months	11 months
Expected Volatility	18872.00%	18862.00%	17079.00%	19958.00%
Expected Dividends	$ 0	$ 0	$ 0	$ 0

Loans Payable (Details Narrativ

Loans Payable (Details Narrative)	3 Months Ended
	Jun. 30, 2018USD ($)	Jan. 08, 2018USD ($)
Promissorry Notes		$ 174,500
Interest Rate of Promissory Note		.05
Loans Payable [Member]
Interst Recorded	$ 2,169
Days due within demand notice	2 days

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative)	3 Months Ended
	Jun. 30, 2018$ / sharesshares	Apr. 19, 2017USD ($)
Date of Forward Split	Mar. 6, 2017
Common stock, par value | $ / shares	$ 0.001
Common Shares Authorized before split	75,000,000
Common stock shares, authorized	1,125,000,000
Foward Split shares after | $ / shares	$ 15
Forward Split shares prior | $ / shares	$ 1
Stock Authorized to Issue	1,125,000
Stock Authorized to Issue, Value per share	0.001
Common Stock Issued and Outstanding	90,000,000
Purchase Price of Pharma Agreement | $		$ 6,000,000
Payable in cash of purchase agreement | $		3,000,000
Amount of financing to be obtained for purchase agreement | $		$ 4,000,000
Closing date of purchase agreement	Sep. 30, 2017
Percentage of Shareholders needed to select all directors of Company	50.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	3 Months Ended
	Jun. 30, 2018USD ($)
Advances from officer	$ 6,907
Advances Outstanding	59,293
Interest Accrued	$ 813
Anderson [Member]
Interst of Advance from officer	0
Promissory Note Issued	$ 32,608
Promissory Note Interest Rate	0.10

Royalty Agreement (Details Narr

Royalty Agreement (Details Narrative)	3 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)
Research and Development [Abstract]
Date of License Agreement	Apr. 4, 2017
Royaly Percentage	0.08
Minimum Royalty per month	$ 10,000
Royalty Expense	$ 30,000	$ 30,000